Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday - Aflac ( NYSE:AFL ) , American Public Education ( NASDAQ:APEI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stephens & Co. cut Atlassian Corporation TEAM price target from $221 to $202.
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia ( NTLA ) Q2 Revenue Jumps 106%
Intellia Therapeutics ( NASDAQ:NTLA ) , a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a significant increase in collaboration revenue to $14.2 million ( GAAP ) for Q2 2025, which beat the ...
Intellia Therapeutics, Inc. ( NTLA ) Reports Q2 Loss, Beats Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new ...
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Intellia Therapeutics ( NASDAQ:NTLA )
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia ( NTLA ) To Contact Him Directly To Discuss Their Options
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - Intellia Therapeutics ( NASDAQ:NTLA )
CAMBRIDGE, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. NTLA, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference ...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in ...
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
Why Is KalVista Pharmaceuticals Stock Soaring On Monday? - KalVista Pharma ( NASDAQ:KALV )
Ekterly approved by FDA as the first oral on-demand treatment for HAE in patients 12 and older. KONFIDENT-S trial showed a median 10-minute treatment time after HAE attack onset. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV )
Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine ( NASDAQ: EDIT ) is a promising clinical-stage company that has captured Wall Street's attention at the ...
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran ( lonvo-z ) in Patients with Hereditary Angioedema ( HAE ) at the European Academy of Allergy and Clinical Immunology Congress - Intellia Therapeutics ( NASDAQ:NTLA )
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the ...
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran ( lonvo-z ) in Patients with Hereditary Angioedema ( HAE ) at the European Academy of Allergy and Clinical Immunology Congress
CAMBRIDGE, Mass., June 15, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing ...
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
How Much Upside is Left in Intellia Therapeutics ( NTLA ) ? Wall Street Analysts Think 398.31%
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Intellia Therapeutics ( NASDAQ:NTLA )
Over 200 patients were dosed, and 365 enrolled in the Nex-Z MAGNITUDE trial, aiming for 765 by early 2027. Intellia plans BLA filing for NTLA-2002 in HAE by late 2026, with a U.S. launch targeted for 2027. Last Chance: Access your full investing command center-trade ideas, screeners, expert ...
HP Posts Downbeat Earnings, Joins SentinelOne, Best Buy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Brooge Energy ( NASDAQ:BROG ) , Best Buy Co ( NYSE:BBY )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of HP Inc. HPQ fell sharply in today's pre-market trading after the company reported worse-than-expected second-quarter adjusted EPS results and issued third-quarter adjusted EPS ...
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - C3.ai ( NYSE:AI ) , Actelis Networks ( NASDAQ:ASNS )
Shares of NVIDIA Corporation NVDA rose sharply in today's pre-market trading after the company posted first-quarter results. The company reported first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 ...
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Intellia Therapeutics ( NASDAQ:NTLA )
NEW YORK, May 22, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran ( nex-z ) , in Patients with Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
CAMBRIDGE, Mass., May 18, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of ...
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran ( nex-z ) , in Patients with Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy at...
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at...
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics ( NTLA ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Medicus Pharma ( NASDAQ:MDCX ) , Marriott International ( NASDAQ:MAR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim cut Intellia Therapeutics, Inc. NTLA price target from $55 to $45.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Intellia Therapeutics, Inc. ( NTLA ) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
C4 Therapeutics, Inc. ( CCCC ) Reports Q1 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 22.92% and 103.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CorMedix ( CRMD ) Surpasses Q1 Earnings and Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
